Your browser is no longer supported. Please, upgrade your browser.
Settings
PHAS PhaseBio Pharmaceuticals, Inc. daily Stock Chart
PHAS [NASD]
PhaseBio Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.09 Insider Own0.10% Shs Outstand30.89M Perf Week-3.62%
Market Cap394.77M Forward P/E- EPS next Y-1.74 Insider Trans- Shs Float22.42M Perf Month89.33%
Income-23.80M PEG- EPS next Q-0.41 Inst Own56.80% Short Float0.65% Perf Quarter250.14%
Sales0.70M P/S563.96 EPS this Y-86.10% Inst Trans- Short Ratio0.32 Perf Half Y155.60%
Book/sh2.08 P/B6.14 EPS next Y-4.90% ROA- Target Price19.00 Perf Year-
Cash/sh1.97 P/C6.47 EPS next 5Y- ROE- 52W Range2.55 - 16.65 Perf YTD313.59%
Dividend- P/FCF- EPS past 5Y- ROI-33.60% 52W High-23.24% Beta-
Dividend %- Quick Ratio13.70 Sales past 5Y- Gross Margin- 52W Low401.18% ATR1.57
Employees24 Current Ratio13.70 Sales Q/Q- Oper. Margin- RSI (14)58.23 Volatility9.22% 14.84%
OptionableNo Debt/Eq0.15 EPS Q/Q-52.00% Profit Margin- Rel Volume0.80 Prev Close13.88
ShortableYes LT Debt/Eq0.15 EarningsMar 26 AMC Payout- Avg Volume462.29K Price12.78
Recom1.50 SMA208.69% SMA5086.11% SMA200154.73% Volume364,823 Change-7.93%
Nov-13-18Initiated Needham Buy $18
Nov-12-18Initiated Stifel Buy $14
Nov-12-18Initiated Citigroup Buy $18
Apr-17-19 04:00AM  PhaseBio completes $49.5M stock sale American City Business Journals
Apr-16-19 04:01PM  PhaseBio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire +9.35%
08:05AM  Billionaires Are Betting This Could Be One Of The Biggest Industries In History ACCESSWIRE
Apr-12-19 11:20AM  PhaseBio plans $43M stock sale American City Business Journals +8.51%
Apr-11-19 09:19PM  PhaseBio Announces Pricing of Public Offering of Common Stock GlobeNewswire
Apr-10-19 07:32AM  The Daily Biotech Pulse: Amgen's Bone-Building Osteoporosis Drug Clears FDA Muster, PhaseBio Offering Benzinga -11.84%
Apr-09-19 04:45PM  PhaseBio Announces Proposed Public Offering of Common Stock GlobeNewswire +16.23%
04:30PM  Why PhaseBio's stock rose 16 percent Tuesday American City Business Journals
03:00PM  Here's Why PhaseBio Pharmaceuticals Rose as Much as 32.5% Today Motley Fool
11:24AM  PhaseBio Stock Up on Breakthrough Therapy Status for PB2452 Zacks
08:10AM  The Daily Biotech Pulse: PhaseBio Gets Breakthrough Therapy Designation, FDA Shoots Down Zogenix Epilepsy Regulatory Filing Benzinga
07:59AM  PhaseBio shares soar 28% premarket as FDA speeds path for approval of PB2452 MarketWatch
07:30AM  Dow Jones Futures: Zogenix Leads 3 Big Movers On FDA News Investor's Business Daily
Apr-08-19 04:01PM  PhaseBio Receives FDA Breakthrough Therapy Designation for PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor GlobeNewswire +17.15%
Apr-07-19 06:00PM  3 Stocks That Have More Than Tripled So Far in 2019 Motley Fool
Mar-26-19 04:01PM  PhaseBio Reports Fourth Quarter and Full-Year 2018 Financial and Business Results GlobeNewswire +32.85%
07:36AM  The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs Benzinga
Mar-25-19 04:30PM  PhaseBio Announces Term Loan of up to $15 Million GlobeNewswire
Mar-19-19 11:57AM  PhaseBio Stock Up on Positive Data From PB2452 Phase I Study Zacks
08:00AM  PhaseBio To Report Fourth Quarter and Full-Year 2018 Financial and Business Results on March 26, 2019 GlobeNewswire
Mar-18-19 07:29AM  PhaseBio's stock more than doubles after positive phase 1 trial results of ticagrelor reversal agent MarketWatch +67.47%
Mar-17-19 03:00PM  Full Results from PhaseBio Phase 1 Clinical Trial of PB2452 Published in the New England Journal of Medicine and Presented at the American College of Cardiologys 68th Annual Scientific Session GlobeNewswire
Mar-06-19 08:00AM  PhaseBio to Present at Cowen and Company 39th Annual Health Care Conference GlobeNewswire
Mar-04-19 08:30AM  PhaseBio Appoints Richard A. van den Broek to Board of Directors GlobeNewswire
08:00AM  PhaseBio Announces Acceptance of Late-Breaking Clinical Trial Submission of PB2452 Phase 1 Clinical Trial Results for Presentation at the American College of Cardiologys 68th Annual Scientific Session GlobeNewswire
Jan-25-19 07:00AM  Johnson & Johnson Is Selling These 2 Biotech Stocks Barrons.com +9.20%
Jan-10-19 02:54PM  A few minutes with... PhaseBio CEO Jonathan Mow American City Business Journals
Dec-18-18 08:00AM  The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan Benzinga +9.60%
Dec-17-18 04:30PM  PhaseBio Appoints Edmund P. Harrigan to Board of Directors GlobeNewswire -8.98%
Nov-30-18 08:25AM  The Daily Biotech Pulse: EC Nod For Shire, Mirati Gets FDA Clearance For Cancer Drug Trials, PhaseBio's First Earnings Benzinga
Nov-29-18 04:30PM  PhaseBio Reports Third Quarter 2018 Financial and Business Results GlobeNewswire
Nov-27-18 08:00AM  PhaseBio Announces Dosing of First Patient in Phase 2b Clinical Trial of PB1046 in Pulmonary Arterial Hypertension GlobeNewswire
Nov-21-18 08:00AM  PhaseBio To Report Third Quarter 2018 Financial and Business Results on November 29, 2018 GlobeNewswire +7.03%
Nov-07-18 08:00AM  PhaseBio to Present at Stifel 2018 Healthcare Conference GlobeNewswire
Oct-17-18 07:24PM  PhaseBio Announces Pricing of Initial Public Offering GlobeNewswire
01:19PM  PhaseBio's IPO: What You Need To Know Benzinga
Oct-15-18 01:10PM  IPO Outlook For The Week: E-Scooters, Drugs And Hotel Service Benzinga
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase 1 clinical trial and is been developed for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. It is also developing PB1046, a fusion protein currently in a Phase 2b clinical trial for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is based in Malvern, Pennsylvania.